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miR-208A Targeted Suppression of PDE4D Directly Enhances Myocyte
Contractile Function via PKA-Mediated Phosphorylation of cTnI and PLN
Fikru B. Bedada, Joseph M. Metzger.
University of Minnesota, St paul, MN, USA.
Molecular inotropy refers to cardiac myocyte contractile status that can be ti-
trated, positively or negatively, to affect overall heart pump performance. Al-
though inotropic drugs have been in clinical practice for many decades, there is
an urgent need to discover new inotropes with unique mechanisms of action for
the treatment of heart failure. Here, we investigate the prospect of micro-RNAs
to directly modify downstream inotropic signaling pathways for improving
contractile function. We focused on miR-208a owing in part to its known re-
stricted expression profile in the myocardium. Results show that acute miR-
208a expression, at 4-5 fold over endogenous miR-208a and independent of al-
tered host myosin gene expression, confers significant positive inotropy and
faster relaxation compared to miR-208a-mutant and untreated control adult car-
diac myocytes (P<0.05). Using in vitro cardiac stress testing, miR-208a ampli-
fied the inotropic and relaxation responses to increased stimulation frequency.
MiR-208a also promoted fast calcium transient decay with no change in peak
calcium accounting in part for enhanced relaxation. To gain insight into mech-
anism, we analyzed in silico putative miR-208a targets, focusing on potential
inotropic signaling targets. Interestingly, we provide evidence that miR-208a
has a direct effect to negatively regulate expression of PDE4D, but does not af-
fect PDE5A in myocytes. Consistent with these findings, phosphorylation of
cTnI and PLN at PKA sites was increased in myocytes after acute miR-208a
expression. Taken together, we show for the first time that miR-208a confers
positive inotropy and enhances relaxation in myocytes by PKA mediated phos-
phorylation of cTnI and PLN through a mechanism of direct suppression of
PDE4D. Because heart failure is associated with decreased phosphorylation
of cTnI and PLN, miR-208a may represent a new therapeutic modality for en-
hancing ventricular myocyte performance via the PDE4D-cAMP-PKA signal-
ing pathway.
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Regulatory Light Chain Phosphorylation Mimic S15D Causes Partial
Rescue of Isometric Force Production in FHC Causing Mutation D166V
William M. Schmidt1, Priya Muthu2, James Watt1, Jeffrey Moore1,
Danuta Szczesna-Cordary2.
1Boston University School of Medicine, Boston, MA, USA, 2University of
Miami Miller School of Medicine, Miami, FL, USA.
Familial hypertrophic cardiomyopathy (FHC) is characterized by a pathological
thickening of the muscle surrounding the heart and is the leading cause for sud-
den cardiac death in young people. There are numerous mutations in sarco-
meric proteins that have been implicated in causing FHC. Myosin, the
molecular motor that powers cardiac muscle contraction, consists of a globular
domain and an elongated a-helical neck region, which is thought to undergo
large conformational changes during muscle contraction. The myosin regula-
tory light chain (RLC) functions to support the neck region, therefore it is
not surprising that several single amino acid substitutions in the RLC have
been implicated in FHC.
Here we studied D166V, an RLC point mutation that is associated with in-
creased left ventricular wall thickness, abnormal electrocardiogram, and de-
creased isometric force and ATPase in skinned fibers from transgenic mouse
hearts. We have expressed porcine cardiac b myosin (the same isoform found
in humans) and replaced the endogenous RLC with a human RLC. The ex-
changed RLC contained either wild type (WT), D166V, S15A, or a double mu-
tant D166V/S15A, or D166V/S15D. The S15D mutation served as
a phosphorylation mimic. We performed frictional loading assays using a mod-
ified in vitromotility assay and determined the average force produced by a bed
of monomeric myosin. While maximal unloaded velocity was unchanged for all
of the mutants studied, the force of D166V and D166V/S15A was significantly
reduced compared to WT, with an additive decrease in the double mutant.
D166V/S15D resulted in a significant increase in force compared to D166V/
S15A and was restored to near WT levels. These results suggest that D166V
causes a reduction in myosin isometric force production and phosphorylation
may act to recover it.
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Physiological Effects of FHC-Causing K104E Mutation in the Myosin
Regulatory Light Chain
Wenrui Huang1, Katarzyna Kazmierczak1, Priya Muthu1, Yingcai Wang1,
Jingsheng Liang1, Ana I. Rojas1, Theodore P. Abraham2,
Danuta Szczesna-Cordary1.
1University of Miami, Miami, FL, USA, 2Johns Hopkins University,
Baltimore, MD, USA.We have studied the physiological effects of the Lysine 104 to Glutamic Acid
(K104E) mutation in the ventricular myosin regulatory light chain (RLC),
shown to cause familial hypertrophic cardiomyopathy (FHC). In vitro and in
vivo experiments were performed using transgenic (Tg) mouse cardiac muscle
preparations carrying the K104E-RLC mutation. We observed a slight but sig-
nificant decrease in maximal force (DFmaxy8kN/m
2) and an increase in the
Ca2þ-sensitivity (DpCa50y0.1) of isometric contraction in glycerinated
skinned muscle fibers from Tg-K104E compared to Tg-WT mice. No mutant
related changes in rigor binding of transgenic K104E mouse myosin to
pyrene-actin were observed. Likewise, no changes in actomyosin or myofibril-
lar ATPase activities were monitored. Histological examination of Masson’s
trichrome stained Tg-hearts showed signs of fibrosis in 8 mo-old Tg-K104E
mice compared to age matched Tg-WT. These observed changes in myocyte
organization in Tg-K104E mice could be due to ~4-fold decrease in the myosin
heavy chain-RLC interaction determined by the binding of bacterially ex-
pressed K104Emutant to RLC-depleted porcine myosin. Echocardiography ex-
amination of senescent Tg-K104E mice confirmed a hypetrophic phenotype
and showed a significantly enlarged interventricular septum and LVPWd
(left ventricular posterior wall in diasole), ~1.6-fold increase in LV mass and
significantly decreased LVIDs (LV inner diameter in systole) compared to
Tg-WT mice. However, EF (ejection fraction) was higher in Tg-K104E mice
(7358%) compared to 6157% observed in Tg-WTmice. In addition, Doppler
E velocity was also 1.3-fold higher in Tg-K104E mice compared to Tg-WT.
These results confirm a mutation induced hypertrophic phenotype in Tg-
K104E mice, similar to the patients carrying this FHC-mutation. No drastic
changes at the level of actomyosin interaction or in cardiac function assessed
in Tg-K104E mice suggest that the mutation might be associated with good
prognosis. Supported by NIH-HL071778 (DSC).
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Myosin Regulatory Light Chain Phosphorylation Rescues Cardiac
Dysfunction Caused by Familial Hypertrophic Cardiomyopathy-Linked
Mutations
Priya Muthu, Katarzyna Kazmierczak, Wenrui Huang, Ana I. Rojas,
Danuta Szczesna-Cordary.
University Of Miami: Miller School of Medicine, Miami, FL, USA.
In this report, we compared the role of cardiac myosin regulatory light chain
(RLC) phosphorylation on cardiac function in skinned muscle preparations
containing two RLC mutations, R58Q (arginine to glutamine) and D166V (as-
partic acid to valine), both linked with a malignant disease phenotype. Previous
studies on D166V-transgenic mice showed that the myosin light chain kinase
(MLCK)-induced phosphorylation of D166V mouse myocardium was able to
alleviate detrimental functional effects caused by this mutation. In this study,
we used recombinant phosphomimetic S15D (serine to aspartate) mutation in
the D166V background exchanged into porcine cardiac myosin and investi-
gated the effect of constitutively phosphorylated RLC proteins on the actomy-
osin interaction. The actin-activated myosin ATPase activity, which was
decreased in D166V- exchanged myosin, was partially rescued in S15D-
D166V exchanged myosin reaching the level observed for WT-reconstituted
myosin. Similarly, myosin reconstituted with S15D-D166V mutant showed
an increase in the binding to fluorescently labeled actin compared to D166V-
reconstituted myosin, with Kd=1.9 mM and Kd=41 mM, respectively. To further
investigate whether MLCK-phosphorylation could rescue the phenotype asso-
ciated with the R58Q mutation, we studied force development in transgenic
R58Q-mouse papillary muscle fibers. Compared to Tg-WT, a drastic reduction
in maximal force and myofibrillar ATPase activity was observed in samples
carrying the R58Q mutation. However, MLCK induced phosphorylation of
R58Q muscle fibers resulted in significantly increased maximal force and myo-
fibrillar ATPase activity. These results suggest that RLC phosphorylation plays
an important role not only in the physiological performance of the heart, but
also helps to maintain normal cardiac function in the diseased myocardium.
Our findings may contribute to the development of targeted cellular therapeutic
approaches to limit FHC related cardiac dysfunction. Supported by AHA-
10POST3420009 (PM) and NIH- HL071778 and HL090786 (DSC).
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Novel Phosphorylation Sites and Reduced Phosphorylation Levels in
Human Cardiac MyBP-C from Failing Hearts
Viola Kooij1, Weihua Ji1, Sheng-bing Wang1, Cris dos Remedios2,
Anne M. Murphy1, Jennifer E. Van Eyk1.
1Johns Hopkins University, Baltimore, MD, USA, 2The University of
Sydney, Sydney, Australia.
Cardiac myosin binding protein-C (cMyBP-C) is a large multidomain protein
associated with the thick filaments. Phosphorylation of cMyBP-C is a regulator
of cardiac contractility and it is known that the phosphorylation status of
558a Tuesday, February 28, 2012cMyBP-C is altered during heart failure (HF). There are several identified phos-
phorylated residues, including the regulatory phosphorylation sites Ser275,
Ser284 and Ser304. Methods: Comparison of the extent of MyBP-C phosphor-
ylation status in failing (N=10) and non-failing (N=10) human left ventricle
(LV) tissue. The myofilament subproteome was extracted using the ‘IN Se-
quence’ method prior to analysis with some samples dephosphorylated using
alkaline phosphatase as control. Sample analysis was carried out using gel-
(e.g. phos-tag) and mass spectrometry (MS)-based methods. Results: Using
an MS-based phospho-peptide (Ti02 chromatography) enrichment strategy
we identified novel phosphorylation sites at residues Ser286 and Thr290, lo-
cated in the M-motif. These sites were as well observed in MyBP-C from
LV canine hearts. A novel site at residue Thr1109, the titin binding domain
C9, was only observed in the samples without phospho-enrichment. Our results
indicate a marked reduction in cMyBP-C phosphorylation at residues Ser284,
Ser286, Thr290 and Thr1109 in end-stage HF compared to the non-failing
group. Conclusion: This study provides evidence for novel phosphorylation
sites on cMyBP-C both in human and canine hearts and reduced phosphoryla-
tion levels in the end-stage failing heart.
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Effects of HCM Missense Mutations in the M Domain of Cardiac
Myosin Binding Protein C on Calcium Sensitivity of Force and Rate in
Rat Trabeculae
Kristina L. Bezold, Samantha P. Harris.
University of California, Davis, Davis, CA, USA.
Recombinant N-terminal domains of cardiac myosin binding protein C
(cMyBP-C) increase calcium-sensitivity of force and the rate of tension rede-
velopement (ktr) when added to permeabilized rat trabeculae. We previously
demonstrated that the regulatory domain of cMyBP-C, referred to as the
MyBP-C motif (or ‘‘M domain’’), is required for these effects. Here we inves-
tigated the effects of single amino acid missense substitutions within the M-do-
main that are associated with human hypertrophic cardiomyopathy (HCM) on
force development and ktr in permeabilized trabeculae from rat right ventricles.
Individual substitutions (R322Q, E330K, V338D, and L348P) were introduced
into a recombinant mouse C1C2 protein (encompassing domains C1-M-C2 of
murine cMyBP-C) by site directed mutagenesis and effects were compared to
wild-type C1C2. All four of the mutations affected the ability of C1C2 to aug-
ment force. Whereas 5 mM wild-type C1C2 induced a pronounced leftward
shift in Ca2þ sensitivity of tension (~0.5 pCa units) and increased ktr at all sub-
maximal Ca2þ concentrations, 3 of the mutations reduced the effects of C1C2.
Another variant increased the efficacy of C1C2 and increased passive force in-
dependent of Ca2þ, but reduced maximal Ca2þ activated force. Together
these results indicate that cMyBP-C variants associated with HCM could di-
rectly disrupt sarcomere contractile properties through gain or loss of func-
tional effects and that at least some cMyBP-C missense mutations may cause
disease through a poison polypeptide mechanism. This work is supported by
NIH HL080367 to SPH and a DOD NDSEG graduate fellowship to KLB.
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Common Mechanical Properties of Recombinant and Native Cardiac
Myosin Binding Protein-C by Atomic Force Microscope
Arpad Karsai1, Miklo´s S.Z. Kellermayer2, Samantha P. Harris1.
1University of Davis, Davis, CA, USA, 2Semmelweis University,
Budapest, Hungary.
Cardiac myosin binding protein-C (cMyBP-C) is a member of the immuno-
globulin (Ig) superfamily of proteins and consists of 8 Ig- and 3 fibronectin
(Fn)-like domains along with a unique regulatory sequence referred to as the
MyBP-C ‘‘motif’’ or M-domain. Previously we used atomic force microscopy
(AFM) to investigate the mechanical properties of the different domains of mu-
rine cMyBP-C expressed using a baculovirus/insect cell expression system. To
investigate whether the mechanical properties of cMyBP-C are conserved
across species, here we used AFM to investigate the mechanical properties
of human recombinant cMyBP-C expressed using a baculovirus/insect cell
expression system and native cMyBP-C purified from bovine heart. AFM
force-extension spectra were obtained from cMyBP-C molecules by randomly
adhering individual molecules to the tip of an AFM cantilever and moving the
cantilever to impose a load that stretched the molecules. Results show that the
spectra for the human recombinant and bovine native proteins are remarkably
similar with the first Ig/Fn-like domain unfolding events occurring at low
(~50 pN) forces and the highest stability domains unfolding at ~190 pN. Exper-
iments also revealed frequent unfolding events that appeared coupled such that
lower stability domains would often unfold after higher stability domains.
These unexpected force ‘‘drops’’ were highly reproducible and occurred in
spectra from both human cMyBP-C and bovine cMyBP-C. In addition, both re-
combinant and native cMyBP-C exhibited an ~100 nm long extensible regionthat could be stretched with less than 50 pN force prior to the unfolding of Ig
and Fn-like domains. Combined with our previous results from mouse cMyBP-
C, these results establish common mechanical features of cMyBP-C across spe-
cies. Supported by NIH HL080367.
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The Effects of C-Terminal Mutations on the Folding of Cardiac Myosin
Binding Protein-C
Ashley Holly1, Tzvia I. Cuperman1, Chad Liber1, Xiang Ji2,
Sakthivel Sadayappan2, Natosha L. Finley1.
1Miami University, Oxford, OH, USA, 2Stritch School of Medicine,
Loyola University Chicago, Maywood, IL, USA.
Cardiac myosin binding protein-C (cMyBP-C) is a modular protein involved in
stabilizing interactions with the thick filament of the sarcomere. The N-termi-
nus of cMyBP-C associates with actin and myosin S2 and the C-terminus inter-
acts with titin and myosin rods. While no high-resolution structure of C-
terminal cMyBP-C exists, disruption of this region is proposed to destabilize
cMyBP-C and adversely affect cardiac structure and function. In particular, de-
letion of 25 base pairs (D25) in the gene encoding for cMyBP-C results in
amino acid substitutions in the C10 domain of cMyBP-C (C10 D25) which
may be associated with the development of hypertrophic and dilated cardiomy-
opathies by unknown molecular mechanisms. The prevalence of this mutation
is approximately 1% of the world population, underscoring the necessity of de-
termining its role(s) in the pathogenesis of cardiomyopathies. In this study, cir-
cular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopies
have been used to examine the conformation of wild-type (Wt) and mutant
C-terminal domains of cMyBP-C. Comparison of near UV CD spectra revealed
alterations in the packing of aromatic residues in C10 D25 suggesting it is less
stably folded as compared to C10 Wt. C10 D25 exhibited less beta-sheet con-
tent than C10 Wt as evidenced by the estimation of secondary structure from
CD data. NMR analyses of amide proton/nitrogen chemical shifts and line-
widths were used to probe the conformation of C10 domains and to map resi-
dues of importance in protein-protein association onto cMyBP-C models.
Taken together, these data suggest that theD25 mutation structurally modulates
cMyBP-C sites involved in binding titin and myosin.
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Human Signaling Scaffold Protein (mAKAP) Binding Kinetics to PKA and
Phosphodiesterase (PDE4DE): Implications for a Possible Role in Heart
Failure
Abeer Rababa’h, John Craft, Cori Wijaya, Bradley K. McConnell.
University of Houston, Houston, TX, USA.
Heart failure is a leading cause of morbidity and mortality in the USA. There
are several therapeutic agents available for heart failure management. In partic-
ular, agents that block beta-adrenergic receptor improve mortality rate among
heart failure patients by enhancing cardiac function. Beta-adrenergic receptor
stimulation signals through protein kinase A (PKA) dependent phosphoryla-
tion, partly by binding to A-kinase anchoring proteins, influencing calcium ho-
meostasis. In particular, mAKAP (muscle-selective A-kinase anchoring
protein) is targeted to specific intracellular compartments resulting in localiza-
tion of PKA with its substrates as well as to bind with ryanodine receptors and
phosphodiesterase-4D3 (PDE4DE). The signal transduction complex formed
by the scaffold protein mAKAP at the perinuclear envelop of striated myocytes
contains cAMP specific binding protein PDE4D3 which is responsible for
cAMP signaling termination. Agents that modify PKA signaling would be ex-
pected to mediate an altered inotropic response. From different genomic data-
bases, we have recently identified fifteen human mAKAP coding non-
synonymous polymorphisms located within or near key protein binding sites
critical to beta-adrenergic receptors signaling. Seven of these mutants were
cloned for the purpose of comparing whether those substitution disrupt mA-
KAP binding to either the PKA binding domain R2alpha or the phosphodiester-
ase PDE4DE. Using surface plasmon resonance (Biacore 2000) we
demonstrate specific binding of wild type mAKAP to PDE4DE. Experiments
were run in triplicate and as twofold serial dilutions to explore the kinetics
of the interaction and analyzed using Scrubber2 with a 1:1 Langmuir model.
Comparative analysis of the binding responses of mutations to mAKAP could
provide important information about how these mutations modulate signaling.
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Single Molecule Studies of a Titin Mutation Linked to Cardiac Disease
Brian R. Anderson1, Julius Bogomolovas2, Siegfried Labeit2,
Henk Granzier1.
1University of Arizona, Tucson, AZ, USA, 2Universitatsmedizin Mannheim,
Mannheim, Germany.
Recently, a mutation in the 10th immunoglobulin(Ig)-like domain in
titin’s elastic I-band was found in a family affected with arrhythmogenic
